Can Oral Ozempic and Label Expansions Revive NVO’s Near-Term Growth?
Novo Nordisk NVO is a dominant player in the GLP-1 space, marketing its semaglutide drugs under brand names Ozempic…
Lilly’s Foundayo hits 1,390 prescriptions in debut week
April 17 (Reuters) – Eli Lilly’s newly launched obesity pill was prescribed 1,390 times in the U.S. as…
After Obtaining Approval for Its Weight Loss Pill, Is It Off to the Races for Eli Lilly Stock?
On April 1, Eli Lilly (NYSE: LLY) and its shareholders received the news they were eagerly awaiting: the…
Eli Lilly Weight-Loss Pill Becomes Available in U.S.
Eli Lilly’s Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration’s approval…
Global drug makers face pricing pressure as China targets affordable healthcare
Global pharmaceutical companies posted mixed earnings in China last year, with some firms warning that 2026 will be…
Eli Lilly and Insilico Medicine forge $2.75bn AI-driven R&D pact
Eli Lilly is joining forces with artificial intelligence (AI)-powered biotech, Insilico Medicine, in a drug discovery and development…
Ozempic Goes Generic —But Not in the US
A drug that helped turn Novo Nordisk into Europe’s most valuable company is about to lose its…
FDA approves high-dose Wegovy shots
Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may help…
2 Top AI Healthcare Stocks to Buy and Hold
Many of the top companies successfully cashing in on artificial intelligence (AI) are in the technology sector. However,…
1 Reason Why I’d Hold This Weight‑Loss Drug Leader Through Any Market Crash
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are locked in a battle around GLP-1 weight-loss drugs.…